Illumina Ventures returned to reinvest in a $21.8m round for the DNA-analysis system developer having led its series A round in 2018.
France-based DNA quantification technology developer Stilla Technologies collected €20m ($21.8m) today in a series B round featuring Illumina Ventures, the corporate venturing arm of genomics technology producer Illumina.
The round included BNP Paribas Développement, a subsidiary of financial services firm BNP Paribas, as well as Kurma Partners, Idinvest Partners, LBO France, TUS Holdings – the holding corporation of Tsinghua University – and Paris Saclay Seed Fund, which represents University of Paris-Saclay.
Founded in 2013, Stilla has developed a device called…
